32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer

A randomized trial

Alexander Rosemurgy, German Luzardo, Jennifer Cooper, Carl Bowers, Emmanuel Zervos, Mark Bloomston, Sam Al-Saadi, Robert Carroll, Hemant Chheda, Larry Carey, Steven Goldin, Shane Grundy, Bruce Kudryk, Bruce Zwiebel, Thomas Black, John Briggs, Paul Chervenick

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

This prospective randomized trial was undertaken to determine the added efficacy of 32P in treating locally advanced unresectable pancreatic cancer. Thirty patients with biopsy proven locally advanced unresectable adenocarcinoma of the pancreas were assessable after receiving 5-fluorouracil and radiation therapy with or without 32P, followed by gemcitabine. Intratumoral 32P dose was determined by tumor size and volume and was administered at months 0, 1, 2, 6, 7, and 8. Tumor cross-sectional area and liquefaction were determined at intervals by computed tomography scan. Tumor liquefaction occurred in 78% of patients receiving 32P and in 8% of patients not receiving 32P, although tumor cross-sectional area did not decrease. Serious adverse events occurred more often per patient for patients receiving 32P (4.2∈±∈3.1 vs. 1.8∈±∈1.9; p∈=∈0.03) leading to more hospitalizations. Death was because of disease progression (23 patients), gastrointenstinal hemorrhage (4 patients), and stroke (1 patient). One patient not receiving 32P and one receiving 32P are alive at 28 and 13 months, respectively. 32P did not prolong survival (7.4∈±∈5.5 months with 32P vs. 11. 5∈±∈8.0 months without 32P, p∈=∈0.16). 32P promoted tumor liquefaction, but did not decrease tumor size. Intratumoral 32P was associated with more serious adverse events and did not improve survival for locally advanced unresectable pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)682-688
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume12
Issue number4
DOIs
StatePublished - Apr 1 2008

Fingerprint

Pancreatic Neoplasms
Therapeutics
Neoplasms
gemcitabine
Survival
Tumor Burden
Fluorouracil
Disease Progression
Pancreas
Adenocarcinoma
Hospitalization
Radiotherapy
Stroke
Tomography
Hemorrhage
Biopsy

All Science Journal Classification (ASJC) codes

  • Surgery
  • Gastroenterology

Cite this

Rosemurgy, A., Luzardo, G., Cooper, J., Bowers, C., Zervos, E., Bloomston, M., ... Chervenick, P. (2008). 32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: A randomized trial. Journal of Gastrointestinal Surgery, 12(4), 682-688. https://doi.org/10.1007/s11605-007-0430-6
Rosemurgy, Alexander ; Luzardo, German ; Cooper, Jennifer ; Bowers, Carl ; Zervos, Emmanuel ; Bloomston, Mark ; Al-Saadi, Sam ; Carroll, Robert ; Chheda, Hemant ; Carey, Larry ; Goldin, Steven ; Grundy, Shane ; Kudryk, Bruce ; Zwiebel, Bruce ; Black, Thomas ; Briggs, John ; Chervenick, Paul. / 32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer : A randomized trial. In: Journal of Gastrointestinal Surgery. 2008 ; Vol. 12, No. 4. pp. 682-688.
@article{ccd60b67250e473f8c178047aabd76d4,
title = "32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: A randomized trial",
abstract = "This prospective randomized trial was undertaken to determine the added efficacy of 32P in treating locally advanced unresectable pancreatic cancer. Thirty patients with biopsy proven locally advanced unresectable adenocarcinoma of the pancreas were assessable after receiving 5-fluorouracil and radiation therapy with or without 32P, followed by gemcitabine. Intratumoral 32P dose was determined by tumor size and volume and was administered at months 0, 1, 2, 6, 7, and 8. Tumor cross-sectional area and liquefaction were determined at intervals by computed tomography scan. Tumor liquefaction occurred in 78{\%} of patients receiving 32P and in 8{\%} of patients not receiving 32P, although tumor cross-sectional area did not decrease. Serious adverse events occurred more often per patient for patients receiving 32P (4.2∈±∈3.1 vs. 1.8∈±∈1.9; p∈=∈0.03) leading to more hospitalizations. Death was because of disease progression (23 patients), gastrointenstinal hemorrhage (4 patients), and stroke (1 patient). One patient not receiving 32P and one receiving 32P are alive at 28 and 13 months, respectively. 32P did not prolong survival (7.4∈±∈5.5 months with 32P vs. 11. 5∈±∈8.0 months without 32P, p∈=∈0.16). 32P promoted tumor liquefaction, but did not decrease tumor size. Intratumoral 32P was associated with more serious adverse events and did not improve survival for locally advanced unresectable pancreatic cancer.",
author = "Alexander Rosemurgy and German Luzardo and Jennifer Cooper and Carl Bowers and Emmanuel Zervos and Mark Bloomston and Sam Al-Saadi and Robert Carroll and Hemant Chheda and Larry Carey and Steven Goldin and Shane Grundy and Bruce Kudryk and Bruce Zwiebel and Thomas Black and John Briggs and Paul Chervenick",
year = "2008",
month = "4",
day = "1",
doi = "10.1007/s11605-007-0430-6",
language = "English (US)",
volume = "12",
pages = "682--688",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "4",

}

Rosemurgy, A, Luzardo, G, Cooper, J, Bowers, C, Zervos, E, Bloomston, M, Al-Saadi, S, Carroll, R, Chheda, H, Carey, L, Goldin, S, Grundy, S, Kudryk, B, Zwiebel, B, Black, T, Briggs, J & Chervenick, P 2008, '32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer: A randomized trial', Journal of Gastrointestinal Surgery, vol. 12, no. 4, pp. 682-688. https://doi.org/10.1007/s11605-007-0430-6

32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer : A randomized trial. / Rosemurgy, Alexander; Luzardo, German; Cooper, Jennifer; Bowers, Carl; Zervos, Emmanuel; Bloomston, Mark; Al-Saadi, Sam; Carroll, Robert; Chheda, Hemant; Carey, Larry; Goldin, Steven; Grundy, Shane; Kudryk, Bruce; Zwiebel, Bruce; Black, Thomas; Briggs, John; Chervenick, Paul.

In: Journal of Gastrointestinal Surgery, Vol. 12, No. 4, 01.04.2008, p. 682-688.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 32P as an adjunct to standard therapy for locally advanced unresectable pancreatic cancer

T2 - A randomized trial

AU - Rosemurgy, Alexander

AU - Luzardo, German

AU - Cooper, Jennifer

AU - Bowers, Carl

AU - Zervos, Emmanuel

AU - Bloomston, Mark

AU - Al-Saadi, Sam

AU - Carroll, Robert

AU - Chheda, Hemant

AU - Carey, Larry

AU - Goldin, Steven

AU - Grundy, Shane

AU - Kudryk, Bruce

AU - Zwiebel, Bruce

AU - Black, Thomas

AU - Briggs, John

AU - Chervenick, Paul

PY - 2008/4/1

Y1 - 2008/4/1

N2 - This prospective randomized trial was undertaken to determine the added efficacy of 32P in treating locally advanced unresectable pancreatic cancer. Thirty patients with biopsy proven locally advanced unresectable adenocarcinoma of the pancreas were assessable after receiving 5-fluorouracil and radiation therapy with or without 32P, followed by gemcitabine. Intratumoral 32P dose was determined by tumor size and volume and was administered at months 0, 1, 2, 6, 7, and 8. Tumor cross-sectional area and liquefaction were determined at intervals by computed tomography scan. Tumor liquefaction occurred in 78% of patients receiving 32P and in 8% of patients not receiving 32P, although tumor cross-sectional area did not decrease. Serious adverse events occurred more often per patient for patients receiving 32P (4.2∈±∈3.1 vs. 1.8∈±∈1.9; p∈=∈0.03) leading to more hospitalizations. Death was because of disease progression (23 patients), gastrointenstinal hemorrhage (4 patients), and stroke (1 patient). One patient not receiving 32P and one receiving 32P are alive at 28 and 13 months, respectively. 32P did not prolong survival (7.4∈±∈5.5 months with 32P vs. 11. 5∈±∈8.0 months without 32P, p∈=∈0.16). 32P promoted tumor liquefaction, but did not decrease tumor size. Intratumoral 32P was associated with more serious adverse events and did not improve survival for locally advanced unresectable pancreatic cancer.

AB - This prospective randomized trial was undertaken to determine the added efficacy of 32P in treating locally advanced unresectable pancreatic cancer. Thirty patients with biopsy proven locally advanced unresectable adenocarcinoma of the pancreas were assessable after receiving 5-fluorouracil and radiation therapy with or without 32P, followed by gemcitabine. Intratumoral 32P dose was determined by tumor size and volume and was administered at months 0, 1, 2, 6, 7, and 8. Tumor cross-sectional area and liquefaction were determined at intervals by computed tomography scan. Tumor liquefaction occurred in 78% of patients receiving 32P and in 8% of patients not receiving 32P, although tumor cross-sectional area did not decrease. Serious adverse events occurred more often per patient for patients receiving 32P (4.2∈±∈3.1 vs. 1.8∈±∈1.9; p∈=∈0.03) leading to more hospitalizations. Death was because of disease progression (23 patients), gastrointenstinal hemorrhage (4 patients), and stroke (1 patient). One patient not receiving 32P and one receiving 32P are alive at 28 and 13 months, respectively. 32P did not prolong survival (7.4∈±∈5.5 months with 32P vs. 11. 5∈±∈8.0 months without 32P, p∈=∈0.16). 32P promoted tumor liquefaction, but did not decrease tumor size. Intratumoral 32P was associated with more serious adverse events and did not improve survival for locally advanced unresectable pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=40849105030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849105030&partnerID=8YFLogxK

U2 - 10.1007/s11605-007-0430-6

DO - 10.1007/s11605-007-0430-6

M3 - Article

VL - 12

SP - 682

EP - 688

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 4

ER -